BioSight
Companies
SUPERNUS PHARMACEUTICALS, INC. logo

SUPN

NASDAQROCKVILLE, MD
SUPERNUS PHARMACEUTICALS, INC.

Supernus develops and commercializes pharmaceutical products across neurology and psychiatry, with an approved product portfolio including Qelbree (for ADHD), Trokendi XR and Oxtellar XR (for epilepsy), Gocovri and Osmolex ER (for Parkinson's disease), Xadago (for Parkinson's disease), Myobloc (for muscle spasticity), Namzaric (for Alzheimer's disease), Apokyn and Onapgo (for Parkinson's disease), and Zurzuvae (for depression). All products in Supernus's pipeline are already approved and marketed rather than in development.

Price history not yet available for SUPN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar